5月22日 - ** 药物开发商Denali Therapeutics（DNLI.O）的股价在盘前交易中下跌7.5%，报17.86美元
** Denali及其合作伙伴Biogen BIIB.O 表示 ，由于其帕金森病药物在中期研究中未能达到主要目标，双方将终止 该药物的开发
** 称该药物BIIB122与安慰剂相比未能延缓疾病进展
** 威廉·布莱尔（William Blair）分析师表示，该数据令人失望，但对其公司投资观点影响甚微
** “我们一直认为该项目风险较高，并将其成功概率建模为10%”——威廉·布莱尔
** Denali公司将继续针对携带特定帕金森病相关基因突变的患者测试该实验性药物
**截至上一交易日 收盘，DNLI今年以来累计上涨16.9%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.